Polymyalgia Rheumatica - Initial Management

Key Points

• PMR occurs after age 50 and causes bilateral shoulder-girdle pain and prolonged morning stiffness.
• True muscle weakness suggests another diagnosis.
• Screen every PMR patient for giant cell arteritis symptoms.
• Use glucocorticoid doses appropriate for PMR rather than GCA when cranial ischemia is absent.
• Failure to improve should trigger diagnostic reassessment.
• Taper gradually and individualize around relapse and toxicity.
• Methotrexate or specialist biologic therapy can reduce steroid burden in selected patients.
• Prevent osteoporosis and other complications of prolonged glucocorticoid therapy.

Algorithm

1. Confirm age, bilateral shoulder symptoms, morning stiffness, inflammatory markers, and functional impact.
2. Assess specifically for headache, jaw claudication, visual symptoms, scalp tenderness, and vascular symptoms of GCA.
3. Evaluate mimics with examination and targeted CBC/CMP, CK, TSH, rheumatoid serologies, or imaging when indicated.
4. Start an appropriate low-to-moderate prednisone dose for uncomplicated PMR.
5. Reassess clinical response within days to weeks and reconsider the diagnosis if response is poor.
6. Taper progressively once stable remission is established.
7. For recurrent relapse or steroid toxicity, involve rheumatology and consider steroid-sparing therapy.
8. Monitor bone, glucose, blood pressure, eye, infection, and functional health during treatment.

Clinical Synopsis & Reasoning

PMR typically presents after age 50 with relatively abrupt bilateral shoulder pain and stiffness, difficulty raising the arms, morning stiffness lasting at least 30 to 45 minutes, and sometimes hip-girdle pain. Constitutional symptoms can occur. True objective muscle weakness is not a defining feature and should prompt evaluation for myopathy, neurologic disease, or severe deconditioning. ESR and CRP are usually elevated but are not specific. Examination often shows painful active and passive shoulder movement from periarticular inflammation without destructive synovitis.

The central diagnostic task is excluding mimics. Elderly-onset rheumatoid arthritis, rotator cuff disease, cervical radiculopathy, inflammatory myositis, hypothyroidism, infection, malignancy, statin myopathy, and fibromyalgia can resemble PMR. Ultrasound can show subdeltoid bursitis, biceps tenosynovitis, or hip inflammation and is helpful when the diagnosis is uncertain. Every patient with suspected PMR should be asked about new headache, scalp tenderness, jaw claudication, visual symptoms, limb claudication, or constitutional features of GCA. Suspected GCA changes urgency and steroid dosing substantially. A dramatic steroid response can support the working diagnosis but should not be used as the sole diagnostic test.

Treatment Strategy & Disposition

Initial therapy is oral glucocorticoid, commonly prednisone in the approximately 12.5 to 25 mg/day range, individualized to body size, severity, comorbidity, and guideline approach. Higher GCA-level doses are not needed for uncomplicated PMR. Symptoms often improve within days, while inflammatory markers fall more gradually. Failure to improve meaningfully should trigger reconsideration of the diagnosis rather than automatic dose escalation.

Tapering should be individualized and based on sustained clinical remission, not simply normalization of CRP. Contemporary recommendations emphasize reducing glucocorticoid exposure while avoiding repeated abrupt tapers that provoke relapse. If relapse occurs, return temporarily to the last effective dose and taper more slowly. Methotrexate may be used as a steroid-sparing agent in patients at high relapse risk or with substantial glucocorticoid toxicity. IL-6 pathway therapy is increasingly used in selected relapsing or steroid-dependent PMR under specialist care. Prevent osteoporosis, hyperglycemia, hypertension, infection, cataract, and other steroid complications. Exercise and physical therapy help restore function after pain improves.

Epidemiology / Risk Factors

• PMR is one of the most common inflammatory rheumatic diseases of older adults.
• Incidence rises after age 50 and peaks in later decades.
• A subset of patients with PMR develop GCA, and some patients with GCA have PMR symptoms.
• The disease course often lasts one to several years rather than a few weeks.

Investigations

Common Mimics

Pharmacology

Prognosis / Complications

• Most patients respond promptly to glucocorticoids and regain function.
• Relapse during taper is common and does not necessarily imply treatment failure.
• Prolonged steroid exposure can cause more morbidity than PMR itself if toxicity is not actively prevented.
• Atypical course, systemic red flags, or steroid nonresponse should prompt reconsideration for malignancy, infection, RA, myositis, or other diagnoses.

Patient Education / Counseling

• Explain that PMR usually requires months of treatment and a gradual taper rather than a short steroid burst.
• Report new headache, vision change, jaw pain with chewing, or focal neurologic symptoms immediately.
• Stay physically active as pain improves to reverse deconditioning.
• Review osteoporosis prevention, vaccinations, glucose and blood pressure monitoring during steroid therapy.
• Do not change the steroid dose repeatedly without a shared taper plan unless urgent symptoms develop.

Notes

The safest PMR strategy is diagnostic humility. Because prednisone rapidly improves many inflammatory and noninflammatory pain syndromes, a steroid response should not end the diagnostic process. Patients who require unexpectedly high doses, relapse immediately at modest tapering, develop objective weakness, or have unusual systemic symptoms deserve reassessment.

Emerging 2026 European recommendations emphasize confirming the diagnosis rather than using a steroid trial diagnostically and aim for shorter glucocorticoid exposure when feasible. Until those recommendations are fully integrated locally, individualized tapering based on established EULAR/ACR principles and current specialist guidance remains appropriate.

References

1. EULAR/ACR Recommendations for Management of Polymyalgia Rheumatica — Link